EC approves Gazyvaro plus bendamustine in follicular lymphoma
The European Commission has approved Roche’s Gazyvaro (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma.
List view / Grid view
News
Aseptic manufacturing training supported by Cherwell Laboratories
15 June 2016 | By Cherwell Laboratories
Cherwell process validation & environmental monitoring product range on display at APDM training course...
Quotient Clinical hosts formulation development and drug delivery seminar series
15 June 2016 | By Quotient Clinical
Quotient Clinical, the Translational Pharmaceutics® company, is holding a series of formulation development and drug delivery seminars this June and July...
FDA approves higher strength Orfadin capsule for HT-1
15 June 2016 | By Victoria White, Digital Content Producer
The FDA has approved a higher strength 20mg capsule of Sobi's Orfadin (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1)...
Encouraging top-line results for APG101 in myelodysplastic syndromes
15 June 2016 | By Victoria White, Digital Content Producer
A Phase I trial showed that APG101 was well tolerated. In addition, the study showed that APG101 efficiently stimulates erythropoiesis in these patients...
Chemo may boost immunotherapy power in ovarian cancer
15 June 2016 | By Victoria White, Digital Content Producer
A study has found that women with ovarian cancer may benefit more from immunotherapy drug treatments if they are given straight after chemotherapy...
Geographical expansion of the Epiomic™ Hospital Admissions Database to now include 28 countries within a single database
15 June 2016 | By Black Swan Analysis
The Black Swan Analysis team has substantially expanded their online database coverage of patient hospital admissions from the original 6 core markets, USA and the Top 5 EU markets, to a total of 28 markets...
Allecra Therapeutics closes €22 Million Series B financing round
15 June 2016 | By Victoria White, Digital Content Producer
The proceeds will fund Phase II development of AAI202 - a novel antibiotic combination designed to treat drug-resistant Gram-negative bacterial infections...
Novartis and MMV expand partnership to develop KAF156
15 June 2016 | By Victoria White, Digital Content Producer
Novartis' KAF156 is one of the first antimalarial drug candidates to enter Phase IIb clinical development in more than 20 years...
Jardiance reduces risk of progressive kidney disease in type 2 diabetes
14 June 2016 | By Victoria White, Digital Content Producer
Jardiance reduced the risk for new-onset or worsening kidney disease by 39% versus placebo in adults with type 2 diabetes with established CV disease...
Shire to license global rights for PF-00547659 from Pfizer
14 June 2016 | By Victoria White, Digital Content Producer
PF-00547659 is an investigational biologic being evaluated for the treatment of moderate-to-severe inflammatory bowel disease (IBD)...
Tecentriq to dominate the bladder cancer market, says GlobalData
14 June 2016 | By Victoria White, Digital Content Producer
The launch of Roche’s Tecentriq will usher in a dramatic change in the treatment paradigm of bladder cancer, according to an analyst with GlobalData...
Ertugliflozin shows significant A1C reductions in type 2 diabetes
14 June 2016 | By Victoria White, Digital Content Producer
Two studies of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints...
Clinical trial to test promising new treatment for chronic cough
14 June 2016 | By Victoria White, Digital Content Producer
If approved, AF-219 would be the first new cough drug in 50 years and offer hope to the millions of people living with chronic cough...
MK-1293 shows non-inferiority to Lantus in two Phase III studies
14 June 2016 | By Victoria White, Digital Content Producer
Merck has announced results from two Phase III studies evaluating MK-1293 for the treatment of people with type 1 and type 2 diabetes...
